Toronto Dominion Bank
GLUE icon

Toronto Dominion Bank’s Monte Rosa Therapeutics GLUE Stock Holding History

Toronto Dominion Bank’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-800
Closed -$5.55K – 1599
2024
Q4 		$5.55K Buy
+800
New +$6K ﹤0.01% 1460

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Toronto Dominion Bank's GLUE Position: Q1 2025 in Review

Toronto Dominion Bank sold out of Monte Rosa Therapeutics (GLUE) in Q1 2025, closing a stake of 800 shares — an estimated $5.55K sold.

Toronto Dominion Bank first reported a position in GLUE in Q4 2024 and held it in 1 quarter. The position peaked at $5.55K in Q4 2024. 105 funds tracked by Wall St. Rank hold GLUE as of Q1 2025.

  • Toronto Dominion Bank reported no remaining Monte Rosa Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Toronto Dominion Bank sold 800 Monte Rosa Therapeutics shares in Q1 2025, an estimated $5.55K.
  • Toronto Dominion Bank first reported a position in Monte Rosa Therapeutics in Q4 2024 and held it in 1 quarter.
  • Toronto Dominion Bank's Monte Rosa Therapeutics position peaked at $5.55K in Q4 2024.
  • 105 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2025.

Based on Toronto Dominion Bank's 13F filing for Q1 2025, filed 15 May 2025.